Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT ID: NCT05536414

Last Updated: 2025-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

337 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-12

Study Completion Date

2025-05-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).

The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Centanafadine + Placebo

Group Type EXPERIMENTAL

Centanafadine

Intervention Type DRUG

capsule

Placebo

Intervention Type DRUG

capsule

Centanafadine + Escitalopram

Group Type EXPERIMENTAL

Centanafadine

Intervention Type DRUG

capsule

Escitalopram

Intervention Type DRUG

capsule

Escitalopram + Placebo

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

capsule

Placebo

Intervention Type DRUG

capsule

Placebo + Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Centanafadine

capsule

Intervention Type DRUG

Escitalopram

capsule

Intervention Type DRUG

Placebo

capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female subjects between 18-65 years of age, with a primary diagnosis of major depressive disorder and in a current major depressive episode.
* History of an inadequate response to at least 1 and no more than 3 antidepressant treatments in the current major depressive episode.

Exclusion Criteria

* Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode.
* Subjects with a lifetime history of schizophrenia spectrum or other psychotic disorder, bipolar or related disorder, neurocognitive disorder, or personality disorder.
* Subjects with a current diagnosis of post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, or eating disorder (including anorexia nervosa or bulimia).
* Sexually active subjects, who could become pregnant, not agreeing to practice 2 sponsor approved methods of birth control or remain abstinent during the trial and for 30 days (females) or 90 days (males) after last dose of study drug.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yuma CNS Research

Yuma, Arizona, United States

Site Status

SanRo Clinical Research Group LLC

Bryant, Arkansas, United States

Site Status

Behavioral Research Specialists-California-Irvine

Glendale, California, United States

Site Status

Sunwise Clinical Research, LLC - Lafayette - IVY - PPDS

Lafayette, California, United States

Site Status

OM Research LLC - Lancaster - ClinEdge - PPDS

Lancaster, California, United States

Site Status

Synergy Research Centers - SRC - ERG - PPDS

Lemon Grove, California, United States

Site Status

ATP Clinical Research

Orange, California, United States

Site Status

NRC Research Institute - Orange - PPDS

Orange, California, United States

Site Status

Prospective Research Innovations

Rancho Cucamonga, California, United States

Site Status

Anderson Clinical Research - ClinEdge - PPDS

Redlands, California, United States

Site Status

Lumos Clinical Research

San Jose, California, United States

Site Status

Syrentis Clinical Research

Santa Ana, California, United States

Site Status

Schuster Medical Research Institute

Sherman Oaks, California, United States

Site Status

Viking Clinical Research Ltd

Temecula, California, United States

Site Status

CNS Clinical Research Group

Coral Springs, Florida, United States

Site Status

Gulfcoast Clinical Research Center

Fort Myers, Florida, United States

Site Status

Clinical Neuroscience Solutions Inc

Jacksonville, Florida, United States

Site Status

South Florida Research Phase I - IV

Miami Springs, Florida, United States

Site Status

Behavioral Clinical Research, Inc

North Miami, Florida, United States

Site Status

Clinical Neuroscience Solutions Inc

Orlando, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

Atlanta Center for Medical Research - CenExel ACMR - PPDS

Atlanta, Georgia, United States

Site Status

iResearch Atlanta - CenExel - PPDS

Decatur, Georgia, United States

Site Status

Psych Atlanta

Marietta, Georgia, United States

Site Status

Accelerated Clinical Trials,LLC

Peachtree Corners, Georgia, United States

Site Status

Northwest Clinical Trials

Boise, Idaho, United States

Site Status

Flourish Research - Andersonville - PPDS

Chicago, Illinois, United States

Site Status

Revive Research Institute

Elgin, Illinois, United States

Site Status

American Medical Research Inc

Oak Brook, Illinois, United States

Site Status

Louisiana Clinical Research, LLC

Shreveport, Louisiana, United States

Site Status

MTP Psychiatry, LLC

Baltimore, Maryland, United States

Site Status

Precise Research Centers - ClinEdge - PPDS

Flowood, Mississippi, United States

Site Status

Psychiatric Care and Research Center

O'Fallon, Missouri, United States

Site Status

Bio Behavioral Health

Toms River, New Jersey, United States

Site Status

Integrative Clinical Trials - Hunt - PPDS

Brooklyn, New York, United States

Site Status

SPRI Clinical Trials, LLC - ERG - PPDS

Brooklyn, New York, United States

Site Status

Fieve Clinical Research

New York, New York, United States

Site Status

Manhattan Behavioral Medicine

New York, New York, United States

Site Status

Finger Lakes Clinical Research

Rochester, New York, United States

Site Status

Richmond Behavioral Associates

Staten Island, New York, United States

Site Status

Patient Priority Clinical Sites LLC

Cincinnati, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Charak Clinical Research Center

Garfield Heights, Ohio, United States

Site Status

Neuro-Behavioral Clinical Research Inc - ClinEdge - PPDS

North Canton, Ohio, United States

Site Status

Cutting Edge Research

Oklahoma City, Oklahoma, United States

Site Status

Summit Research Network, Inc. - Portland - Headlands - PPDS

Portland, Oregon, United States

Site Status

Suburban Research Associates - ATLAS - West Chester - PPDS

West Chester, Pennsylvania, United States

Site Status

LLM Research - South Carolina

Myrtle Beach, South Carolina, United States

Site Status

Clinical Neuroscience Solutions Inc

Memphis, Tennessee, United States

Site Status

FutureSearch Trials of Dallas, LLC - IVY - PPDS

Dallas, Texas, United States

Site Status

InSite Clinical Research, LLC

DeSoto, Texas, United States

Site Status

Houston Mind & Brain

Houston, Texas, United States

Site Status

Innovative Medical Research of Texas

Houston, Texas, United States

Site Status

Red Oak Psychiatry Associates P A

Houston, Texas, United States

Site Status

University Hills Clinical Research

Irving, Texas, United States

Site Status

AIM Trials

Plano, Texas, United States

Site Status

Grayline Clinical Drug Trials

Wichita Falls, Texas, United States

Site Status

Alpine Research Organization, Inc

Clinton, Utah, United States

Site Status

Cedar Clinical Research - IVY - PPDS

Draper, Utah, United States

Site Status

The Memory Clinic

Bennington, Vermont, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Core Clinical Research

Everett, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

405-201-00062

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.